** Shares of heart company Anteris Technologies slide 12.3% to $5.26 in their Nasdaq debut
** Stock opened for trading at $6, valuing the company at $215.6 mln
** AVR sold 14.8 mln shares in its New York IPO at $6/shr to raise $88.8 mln
** Offering priced at a 11.5% discount to the Dec. 5 closing price of its shares on the Australian Securities Exchange
** TD Cowen, Barclays and Cantor were the joint book-running managers for the offering
** AVR will use the proceeds to fund the development of its transcatheter heart valve, among other purposes
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。